SBI Securities
RARE icon

SBI Securities’s Ultragenyx Pharmaceutical RARE Stock Holding History

SBI Securities’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.9K Buy
657
+524
+394% +$12.6K ﹤0.01% 1849
2026
Q2 		$4.44K Sell
133
-70
-34% -$1.74K ﹤0.01% 2226
2026
Q1 		$4.25K Buy
203
+29
+17% +$653 ﹤0.01% 2102
2025
Q4 		$4K Buy
174
+140
+412% +$4.6K ﹤0.01% 2109
2025
Q3 		$1.02K Buy
34
+19
+127% +$570 ﹤0.01% 2686
2025
Q2 		$545 Hold
15
– – ﹤0.01% 2932
2025
Q1 		$543 Buy
15
+14
+1,400% +$582 ﹤0.01% 2838
2024
Q4 		$42 Buy
+1
New +$50 ﹤0.01% 3674

Other funds holding RARE

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Pinnacle Associates
Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return
Harbor Capital Advisors
Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return
L. Roy Papp & Associates
L. Roy Papp & Associates Phoenix, Arizona $981M AUM 26.21% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

SBI Securities's RARE Position: Q3 2026 in Review

SBI Securities increased its Ultragenyx Pharmaceutical (RARE) stake by 394% in Q3 2026, buying an estimated $12.6K and bringing the position to 657 shares worth $9.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1849.

SBI Securities first reported a position in RARE in Q4 2024 and has held it in 8 quarters since. 21 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

  • SBI Securities held 657 shares of Ultragenyx Pharmaceutical worth $9.9K as of Q3 2026.
  • SBI Securities bought 524 Ultragenyx Pharmaceutical shares in Q3 2026, an estimated $12.6K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #1849 holding.
  • SBI Securities first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and has held it in 8 quarters since.
  • 21 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.